

| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 724.97 | 621.05 | 522.90 | 341.99 | 242.49 |
| Total Expenses | 610.98 | 508.88 | 431.45 | 270.26 | 207.73 |
| Profit Before Tax | 81.90 | 112.17 | 91.45 | 71.73 | 34.75 |
| Profit After Tax | 48.71 | 83.29 | 71.95 | 54 | 27.47 |
| Operating Profit After Depreciation | 119.93 | 114.58 | 97.86 | 77.34 | 40.34 |
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 427.16 | 263.23 | 205.60 | 186.31 | 85.19 |
| Total Non Current Assets | 600.09 | 309.81 | 229.31 | 197.04 | 110.86 |
| Total Current Assets | 495.81 | 457.13 | 429.57 | 216.23 | 121.04 |
| Total Assets | 1,095.90 | 766.94 | 658.88 | 413.27 | 231.89 |
| Total Shareholder's Fund | 674 | 593.96 | 522.27 | 166.93 | 111.81 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 118.34 | 125.17 | 65.53 | -11.93 | 27.96 |
| Net Cash Used In Investing Activities | -223.94 | -365.36 | -33.04 | -120.72 | -101.21 |
| Net Cash Used In Financing Activities | 261.12 | 239.36 | -12.25 | 140.26 | 72.11 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,008.17 | 701.37 | 621.05 | 522.90 | 341.94 |
| Total Expenses | 794.59 | 600.51 | 508.83 | 431.45 | 270.21 |
| Profit Before Tax | 213.58 | 69.11 | 112.22 | 91.45 | 71.73 |
| Profit After Tax | 159.55 | 43.68 | 83.34 | 71.95 | 54 |
| Operating Profit After Depreciation | 219.43 | 106.76 | 114.64 | 97.86 | 77.34 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 499.23 | 357.06 | 226.37 | 178.95 | 160.61 |
| Total Non Current Assets | 766.64 | 603.44 | 304.75 | 227.90 | 197.15 |
| Total Current Assets | 771.31 | 467.81 | 454.71 | 426.71 | 213.14 |
| Total Assets | 1,537.95 | 1,071.25 | 759.46 | 654.61 | 410.29 |
| Total Shareholder's Fund | 1,311.60 | 675.12 | 586.79 | 518 | 163.95 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 115.93 | 100.85 | 55.73 | -9.69 | 26.92 |
| Net Cash Used In Investing Activities | -234.37 | -337.32 | -20.47 | -122.47 | -100.74 |
| Net Cash Used In Financing Activities | 273.56 | 235.48 | -14.44 | 140.26 | 72.11 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 306.20 | 207.24 | 308.48 | 274.99 | 246.73 |
| Total Expenses | 210.87 | 156.33 | 223.52 | 206.32 | 197.80 |
| Profit Before Tax | 96.19 | 58.08 | 82.84 | 63.33 | 50.04 |
| Profit After Tax | 71.86 | 44.01 | 62.72 | 45.45 | 37.57 |
| Operating Profit after Depreciation | 105.17 | 66.85 | 90.74 | 70.34 | 57.37 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 305.19 | 205.97 | 304.16 | 270.94 | 243.59 |
| Total Expenses | 208.59 | 154.98 | 220.10 | 204.29 | 195.46 |
| Profit Before Tax | 97.28 | 58.93 | 82.81 | 62.54 | 50.02 |
| Profit After Tax | 72.89 | 44.65 | 62.85 | 45.31 | 37.68 |
| Operating Profit after Depreciation | 105.57 | 67.01 | 89.75 | 68.82 | 56.71 |
₹1.5/Share
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
| Fund Name | AUM |
|---|---|
| SBI Healthcare Opportunities Fund | 3.81% |
| Bank of India Small Cap Fund | 3.20% |
| Kotak MNC Fund | 3.12% |
| ITI Small Cap Fund | 2.76% |
| UTI-Small Cap Fund | 1.84% |
Acutaas Chemicals rallied 4.82% to Rs 1,627 after the company's consolidated net profit surged 93.52% to Rs 72.24 crore on 24.1% jump in revenue from operations to Rs 306.19 crore in Q2 Septemerb 2025 over Q2 September 2024.
17 Oct 2025, 01:59 pm
On 17 October 2025
10 Oct 2025, 05:08 pm
On 25 September 2025
03 Sep 2025, 03:55 pm
Acutaas Chemicals soared 7.13% to Rs 1305.85 after the company posted robust Q1 FY26 earnings.
31 Jul 2025, 02:23 pm
On 30 July 2025
25 Jul 2025, 11:10 am

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.